Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
Publication
, Journal Article
Gurbel, PA; Tantry, US
Published in: Curr Opin Investig Drugs
March 2008
Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.
Duke Scholars
Published In
Curr Opin Investig Drugs
ISSN
1472-4472
Publication Date
March 2008
Volume
9
Issue
3
Start / End Page
324 / 336
Location
England
Related Subject Headings
- Thromboembolism
- Thiophenes
- Structure-Activity Relationship
- Prasugrel Hydrochloride
- Platelet Aggregation Inhibitors
- Piperazines
- Pharmacology & Pharmacy
- Patents as Topic
- Humans
- Clinical Trials, Phase III as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., & Tantry, U. S. (2008). Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Curr Opin Investig Drugs, 9(3), 324–336.
Gurbel, Paul A., and Udaya S. Tantry. “Prasugrel, a third generation thienopyridine and potent platelet inhibitor.” Curr Opin Investig Drugs 9, no. 3 (March 2008): 324–36.
Gurbel PA, Tantry US. Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Curr Opin Investig Drugs. 2008 Mar;9(3):324–36.
Gurbel, Paul A., and Udaya S. Tantry. “Prasugrel, a third generation thienopyridine and potent platelet inhibitor.” Curr Opin Investig Drugs, vol. 9, no. 3, Mar. 2008, pp. 324–36.
Gurbel PA, Tantry US. Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Curr Opin Investig Drugs. 2008 Mar;9(3):324–336.
Published In
Curr Opin Investig Drugs
ISSN
1472-4472
Publication Date
March 2008
Volume
9
Issue
3
Start / End Page
324 / 336
Location
England
Related Subject Headings
- Thromboembolism
- Thiophenes
- Structure-Activity Relationship
- Prasugrel Hydrochloride
- Platelet Aggregation Inhibitors
- Piperazines
- Pharmacology & Pharmacy
- Patents as Topic
- Humans
- Clinical Trials, Phase III as Topic